# US 2021/0330579 A1 · Skin care formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330579 A1
- Document ID: US20210330579A1
- Status: Published application
- Kind: A1
- Application number: 16/322,703
- Filed: 2017-08-01
- Published: 2021-10-28
- Earliest claimed: 2016-08-01
- Assignees: Embryogenesis Pty Ltd
- Applicants: Embryogenesis Pty Ltd
- Inventors: Peter Britton; Andrew French
- Web page: https://patentgrep.com/patent/US20210330579A1

## CPC

- A61K 8/983: {Blood, e.g. plasma}
- A61K 8/14: Liposomes; Vesicles
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/86: Polyethers
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

There is provided a formulation for skin rejuvenation comprising lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine; a transdermal carrier; and a liposomal base, wherein at least a portion of the lyophilised umbilical cord plasma and transdermal carrier are contained within liposomes of the liposomal base. There is also provided a dosage form for skin rejuvenation comprising 1-5% (w/w) lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine; 85-95% (w/w) polyethylene glycol; and 0.1-2% (w/w) gum acacia.

## Claims

### Claim 1

A formulation for skin rejuvenation comprising:
lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine;
a transdermal carrier; and
a liposomal base,
wherein at least a portion of the lyophilised umbilical cord plasma and transdermal carrier are contained within liposomes of the liposomal base.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein the lyophilised umbilical cord plasma is present in an amount selected from the group consisting of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, and 80%.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the chemokine is selected from the group consisting of eotaxin, IP-10, MCP-1, MIP-1α, MIP-1β and RANTES.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the growth factor is selected from the group consisting of VEGF, G-CSF, bFGF, TGF-1β, GDF-11 and PDGF-BB.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the cytokine is selected from the group consisting of IL1-receptor agonist, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL17A, GM-CSF, TNFα and IFN-γ.

### Claim 6 (depends on 1, 5)

The formulation of claim 1, 5 wherein the lyophilised umbilical cord plasma comprises:
eotaxin, IP-10, MCP-1, MIP-1α, MIP-1β and RANTES; and
VEGF, G-CSF, bFGF, TGF-β1, GDF-11 and PDGF-BB; and
IL1-receptor agonist, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL17A, GM-CSF, TNFα and IFN-γ.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein any one of the active chemokine, growth factor and cytokine is present in an amount selected from the group consisting of about 0.1-1000 pg/g, about 1-1000 pg/g, about 50-1000 pg/g, about 100-1000 pg/g, about 200-1000 pg/g, about 300-1000 pg/g, about 400-1000 pg/g, about 500-1000 pg/g, about 600-1000 pg/g, about 700-1000 pg/g, about 800-1000 pg/g, about 900-1000 pg/g, about 1-100 ng/g, about 10-100 ng/g, about 10-100 ng/g, about 20-100 ng/g, about 30-100 ng/g, about 40-100 ng/g, about 50-100 ng/g, about 60-100 ng/g, about 170-100 ng/g, about 80-100 ng/g, about 90-100 ng/g, and at least about 100 ng/g of dosage form.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the transdermal carrier is selected from the group consisting of isopropyl alcohol, dipropylene glycol methyl-ether, butylated hydroxytoluene dipropylene glycol monomethyl-ether, 1-methoxy 2-propanol (glysolv PM/Icinol PM), Ethylene glycol monobutylether (butyl glyxolv/butyl icinol), Butyl di glysolv (butyl-icinol), Transcutol, propylene glycol (PG), N-methyl-2 pyrrolidone (NMP), methylene chloride, diethyl ether, ethanol, acetonitrile, ethyl acetate, benzyl alcohol, a combination of natural oil; ethylene glycol, propylene glycol, dimethyl polysiloxane (DMPX), oleic acid, caprylic acid, 1-octanol, ethanol (denatured or anhydrous), liposomal compositions, suitable plant oils, such as Aloe vera derivatives or sesame seed oil or derivatives thereof, acrylic polymers, rubber-based polymers, polysiloxane-based polymers, polyvinylpyrrolidone-based polymers, dimethylsulfoxide (DMSO), dimethylformamide (DMF), lecithin, vesicular aggregates, ethosomes, azone, castor oil derivatives, such as ethoxylated castor oil, jojoba oil derivatives, corn oil derivatives, propylene glycol, and emu oil derivatives.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the transdermal carrier is present in an amount selected from the group consisting of 1% (w/w) 2% (w/w), 3% (w/w), 4% (w/w), 5% (w/w), or 6%, 7% (w/w), 8% (w/w), 9% (w/w), 10% (w/w), 11% (w/w), 12% (w/w), 13% (w/w), 14% (w/w), 15% (w/w), 16% (w/w), 17% (w/w), 18% (w/w), 19% (w/w), 20% (w/w), 21% (w/w), 22% (w/w), 23% (w/w), 24% (w/w), 25% (w/w), 26% (w/w), 27% (w/w), 28% (w/w), 29% (w/w), 30% (w/w), 29% (w/w), 30% (w/w), 31% (w/w), 32% (w/w), 33% (w/w), 34% (w/w), 35% (w/w), 36% (w/w), 37% (w/w), 38% (w/w), 39% (w/w), 40% (w/w), 41% (w/w), 42% (w/w), 43% (w/w), 44% (w/w), 45% (w/w), 46% (w/w), 47% (w/w), 48% (w/w), 49% (w/w), and 50% (w/w).

### Claim 10 (depends on 1, 9)

The formulation of claim 1, 9 wherein the liposomal base is an emulsion including a lipophilic component and an aqueous component.

### Claim 11 (depends on 10)

The formulation of claim 10 wherein the liposomal base is a mixture of about 60-80% wt/wt water, glycerin, C12-15 alkyl benzoate, glyceryl stearate, dimethicone, cetearyl alcohol, cetearyl glucoside, polyacrylamide, cetyl alcohol, magnesium aluminum silicate, xanthan gum, aloe vera, tocopheryl acetate, prunus amygadalus amara kernel oil, Vitis vinifera seed extract, Triticum vulgare germ oil, retinyl palmitate, ascorbyl palmitate, Pro-Lipo Multi-emulsion Liposomic System, tetrasodium EDTA, phenoxyethanol, and sodium hydroxymethylglycinate.

### Claim 12 (depends on 1)

The formulation of claim 1, further comprising a transdermal enhancer.

### Claim 13 (depends on 12)

The formulation of claim 12 wherein the transdermal enhancer is selected from the group consisting of ethyl alcohol, isopropyl alcohol, butyl alcohol, benzyl alcohol, ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol trimethylene glycol, glycerin, sorbitol, polyethylene glycol, polyoxyethylene-4-lauryl ether, polyoxyethylene-2-oleyl ether, polyoxyethylene-10-oleyl ether, cotton seed oil, corn oil, safflower oil, olive oil, castor oil, squalene, lanolin; propyl oleate, decyl oleate, isopropyl palmitate, glycol palmitate, glycol laurate, dodecyl myristate, isopropyl myristate, glycol stearate, oleyl alcohol, oleamide, dimethyldecylphosphoxide, methyloctylsulfoxide, dimethyllaurylamide, dodecylpyrrolidone, isosorbitol, dimethylacetonide, dimethylsulfoxide, decylmethylsulfoxide, dimethylformamide; salicylic acid; benzyl nicotinate; lauryl sulfate, sorbitol, polysorbate, linoleic acid, triacetin, ascorbic acid, panthenol, butylated hydroxytoluene, tocopherol, tocopherol acetate, and tocopheryl linoleate.

### Claim 14 (depends on 1)

The formulation of claim 1, comprising:
1 to 80% (v/w) of the lyophilized plasma;
1% to 50% (w/w) of the transdermal carrier; and
up to 80% (w/w) of the liposomal base.

### Claim 15 (depends on 1)

The formulation of claim 1, in a nasal dosage form or an oral dosage form selected from the group consisting on of a sublingual troche, a tablet, a wafer, a lozenge, and a buccal troche.

### Claim 16

A dosage form for skin rejuvenation comprising:
1-5% (w/w) lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine;
85-95% (w/w) polyethylene glycol; and
0.1-2% (w/w) gum acacia.

### Claim 17 (depends on 16)

The dosage form of claim 16 wherein the chemokine is selected from the group consisting of eotaxin, IP-10, MCP-1, MIP-1α, MIP-1β and RANTES; the growth factor is selected from the group consisting of VEGF, G-CSF, bFGF, TGF-β1, GDF-11 and PDGF-BB; and the cytokine is selected from the group consisting of IL1-receptor agonist, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL17A, GM-CSF, TNFα and IFN-γ.

### Claim 18 (depends on 16)

The dosage form of claim 16, wherein the lyophilised umbilical cord plasma comprises:
eotaxin, IP-10, MCP-1, MIP-1α, MIP-1β and RANTES; and
VEGF, G-CSF, bFGF, TGF-β1, GDF-11 and PDGF-BB; and
IL1-receptor agonist, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL17A, GM-CSF, TNFα and IFN-γ.

### Claim 19 (depends on 16)

The dosage form of claim 16, further comprising a transdermal enhancer, enhancer or both a transdermal enhancer and an enhancer.

### Claim 20 (depends on 16)

The dosage form of claim 16, wherein the lyophilised umbilical cord plasma is present in an amount selected from the group consisting of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, and 80%.

### Claim 21 (depends on 16)

The dosage form of claim 16, wherein any one of the active chemokine, growth factor or cytokine is present in an amount selected from the group consisting of about 0.1-1000 pg/g, about 1-1000 pg/g, about 50-1000 pg/g, about 100-1000 pg/g, about 200-1000 pg/g, about 300-1000 pg/g, about 400-1000 pg/g, about 500-1000 pg/g, about 600-1000 pg/g, about 700-1000 pg/g, about 800-1000 pg/g, about 900-1000 pg/g, about 1-100 ng/g, about 10-100 ng/g, about 10-100 ng/g, about 20-100 ng/g, about 30-100 ng/g, about 40-100 ng/g, about 50-100 ng/g, about 60-100 ng/g, about 170-100 ng/g, about 80-100 ng/g, about 90-100 ng/g, and at least about 100 ng/g of dosage form.

### Claim 22 (depends on 16)

The dosage form of claim 16, containing an amount selected from the group consisting of about 0.1 mg, 0.5 mg, 1.0 mg, 5 mg, 10 mg, 15 mg, 25 mg, 35 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg 240 mg, 245 mg, and 250 mg of lyophilised plasma per dosage form.

### Claim 23 (depends on 16)

The dosage form of claim 16, wherein the dosage form is an oral dosage form selected from the group consisting of a sublingual troche, a tablet, a wafer, a lozenge, a buccal troche.

### Claim 24 (depends on 1)

A method of treating, preventing or ameliorating a symptom or sign of a skin defect, the method comprising administering to a subject in need thereof, a composition selected from the group consisting of the formulation of claim 1 and a dosage form comprising 1-5% (w/w) lyophilised umbilical cord plasma comprising at least one active chemokine, at least one growth factor and at least one cytokine, 85-95% (w/w) polyethylene glycol; and 0.1-2% (w/w) gum acacia.

### Claim 25 (depends on 24)

The method of claim 24, wherein the dosage form or formulation is administered at least once per day.

### Claim 26 (depends on 24)

The method of claim 24, wherein the skin defect is selected from the group consisting of poor skin texture, wrinkles, fine lines, UV induced skin damage, skin aging, dry skin, hair follicle deterioration, alopecia, dermatitis, eczema, rash, pruritus, sun burn, burns, stretch marks, acne scars, and surgical scars.

### Claim 27 (depends on 26)

The method of claim 26 wherein the skin defect is wrinkles or fine lines and the treatment reduces the number of wrinkles or fine lines by an amount selected from the group consisting of up to 5%, up to 10%, up to 20%, up to 30%, up to 40% and at least 50%, compared to the number of wrinkles or fine lines before the treatment.
